Kornimate/medical-research-clean huggingface dataset:
comprehensive data collection and follow-up for patients with thyroid, parathyroid and adrenal disease

Conditions: Endocrine Disease

Summary: the goal of this data review study is to collect data to learn more about thyroid, parathyroid, and adrenal disease.

if participant or participant's child agrees to take part in this study, information from the medical record will be recorded and entered into a research database at md anderson. researchers will use this data to learn more about participant's or participant's child's current or suspected illness, surgery, and/or recovery as well as participant's or participant's child's medical history. length of study participant's or participant's child's active participation on this study will be over after 15 years. follow-up phone calls starting about 2-3 years after participant's or participant's child's testing and/or diagnosis and/or treatment and continuing for up to 15 years after participant's surgery, a member of the research team will contact participant by phone to follow up and see how participant or participant's child are doing. the first time participant receives a phone call or are asked in the clinic, participant will be asked for participant's verbal consent for participant or, if this is for participant's child, on behalf of participant's child, to speak to the member of the research team before participant or participant's child are asked any questions. after participant agrees, participant or participant's child will be asked a series of questions related to participant's or participant's child's disease (takes about 20-30 minutes) that ask about participant's or participant's child's current medical status and medical history. each phone call should take 20-30 minutes to complete. if participant or participant's child are scheduled for a routine clinic visit around the time of participant's or participant's child's next follow-up phone call, the research team member may talk to participant or participant's child in person at that time, or a questionnaire can be mailed to participant or participant's child if needed. this is an investigational study. up to 15,000 patients will be enrolled in this study. all will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. all patients that are being seen at md anderson with diagnosed or suspected endocrine disease. patients will be selected from patients undergoing evaluation and/or treatment in the endocrine center, either by selection from a participating endocrine physician or by screening from study personnel for patients scheduled to be seen in the endocrine clinic. 2. in addition, we intend to contact family members of patients who are enrolled on the study, and found to be deceased at follow-up, to request permission to obtain cause of death, to determine whether cause of death may be related to endocrine disease. exclusion criteria: n/a

Keywords: endocrine disease thyroid disease parathyroid disease adrenal disease data review database
food interaction study on the pharmacokinetics of eurartesim™ (dha and pqp)in healthy male adult volunteers

Conditions: Malaria, Falciparum

Summary: the study was designed to assess the effect of food on the extent and rate of absorption of dihydroartemisinin (dha) and piperaquine phosphate (pqp) administered as a fixed dose combination (eurartesim™).


Eligibility criteria:
inclusion criteria: * caucasian healthy males aged between 18 and 50 years(inclusive). * body mass index (bmi) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body weight of 75 kg. * agreed to use two approved methods of contraception from screening and until 90 days after administration of the study drug * had given written informed consent to participate in this study in accordance with local regulations. exclusion criteria: * had received or was anticipated to receive a prescription medication within 14 days prior to the start of dosing or an over-the-counter medicine 48 hours prior to the start of dosing. * abnormal laboratory test results deemed clinically significant by the medical officer. * positive urine drug test (e.g. opiates and cannabinoids) or alcohol breath test. * history of significant drug allergies or significant allergic reaction. * receipt of blood or blood products, or loss or donation of 450 ml or more of blood within 90 days before the first dose administration.
a study to identify the risk of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of dapagliflozin/pioglitazone combination therapy

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to identify the risk of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of dapagliflozin/pioglitazone combination therapy


Eligibility criteria:
inclusion criteria: * among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1) * those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study. exclusion criteria: * those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1). * those who are expected to need insulin prescription during the study period.
the study to evaluate the safety of ub-421 in combination with antiretroviral therapy (art) and the efficacy in reduction of hiv viral load and proviral dna as compared to art alone in art-experienced viremic hiv-1 patients

Conditions: HIV-1 Infection

Summary: this study assess the safety, tolerability, and efficacy in reducing viral load and proviral dna of ub-421 administered as an add-on to the art in art-experienced viremic hiv-1 subjects.


Eligibility criteria:
inclusion criteria: 1. hiv-1 seropositive 2. male with body weight ≥ 50 kg or female with body weight ≥ 45 kg. 3. have been receiving antiretroviral therapy (art) for more than 2 years exclusion criteria: 1. any previous exposure to a mab within 12 weeks prior to the first dose of ub-421 treatment. 2. any significant diseases (other than hiv-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined during the screening period, medical history, and/or physical examination that, in investigator's opinion, would preclude the subject from participating in this study. 3. history of anaphylaxis to monoclonal antibodies. 4. any vaccination within 8 weeks prior to the first dose of ub-421.

Keywords: hiv ub-421
bipolar hemostatic forceps versus standard therapy in acute non-variceal upper gi bleeding

Conditions: Gastrointestinal Hemorrhage

Summary: bipolar hemostatic forceps will be tested against standard therapy in active, non-variceal, upper gastrointestinal bleeding by a prospective, randomized trial

patients with active, non-variceal, upper gastrointestinal bleeding usually need an urgent endoscopic treatment. the standard therapy by application of an hemoclip and/or injection of an epinephrine solution is not always successful. bipolar hemostatic forceps is already being used successfully for the treatment of gastrointestinal bleeding in endoscopic submucosal dissection. its use in primary endoscopic treatment of non-variceal, upper gastrointestinal bleeding has not been shown yet in a randomized prospective study. patients with active, non-variceal, upper gastrointestinal bleeding (esophagus or stomach or duodenum) of any cause are randomized (1:1) in standard therapy by combination therapy using an hemoclip and/or injection of an epinephrine solution or experimental therapy by application of the bipolar hemostatic forceps. cross over-treatment should be tried first in case of failed initial treatment. rescue treatment by other methods such as application of an over the scope clip (otsc), angiographic embolization or surgery will be allowed next. all patients receive an additional standard therapy by proton pump inhibitors (ppi). hypothesis: endoscopic therapy by application of the bipolar hemostatic forceps is superior to standard therapy regarding technical success and rebleeding rate.

Eligibility criteria:
inclusion criteria: * active, nonvariceal, upper gastrointestinal bleeding exclusion criteria: * severe coagulopathy unresponsive to blood products transfusions: platelets \ 3.0; partial thromboplastin time \>2 normal

Keywords: hemostasis, endoscopic; randomized controlled trial
use of anesthetic block for the prevention of in hospital delirium in patients of the orthogeriatric clinical care center of the hufsfb and husji from 2019 - 2020

Conditions: Delirium in Old Age; Fragility Fracture; Hip Fractures

Summary: the purpose of this study is to identify the association between analgesic management with blockade of the iliac fascia versus intravenous analgesia with the presence of delirium during hospital stay in patients admitted to the orthogeriatric clinical care center, to determine the opioid consumption of both groups of patients during hospitalization and determine the risk factors that may be associated with a greater presentation of delirium.

nowadays, with the increase in the geriatric population, there is evidence of an increase in the prevalent conditions in this group, finding within them fragility hip fractures. additionally, most of these patients have a large number of associated comorbidities, which may require greater specialization in care. to reduce the possible complications that may be related, different management protocols have been implemented, including pain management strategies such as preventive analgesics, regional blocks, and early surgery. conventional treatment with the use of intravenous medications can have unwanted effects in geriatric patients with hip fracture, especially in those with greater comorbidity, since medications such as opioids can cause multiple adverse effects, including delirium. also, not treating pain properly can cause complications such as depression and ulcers in addition to delirium. this is why the objective of this study is to define whether there is any association between the presentation of delirium in patients over 65 years of age with hip fracture who undergo iliac fascia block upon admission compared to those who receive only iv analgesia therefore, this retrospective cohort study will be carried out with which it is sought to contribute to the knowledge to continue carrying out early pain management, with the aim of achieving better pain control, a decrease in opioid consumption and thus having a lower number of patients with delirium during hospitalization.

Eligibility criteria:
inclusion criteria: * patients over 65 years of age with a diagnosis of hip fracture due to fragility who are admitted to the orthogeriatric clinical care center at the santa fe de bogotá foundation and the san josé infantil university hospital between january 2019 and december 2020. these two institutions are selected since they have a model of care for this type of patient, it is similar and therefore comparable. exclusion criteria: * patients diagnosed with delirium on admission to the emergency room. * patients with hip fracture caused by high energy trauma * patients with hip fracture related with tumoral disease or metastasis
the value of ceus in assessing the response of cervical lymph nodes after naci for hnscc

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: the head and neck squamous cell carcinoma is the sixth most common malignant tumor worldwide. for patients with locally advanced head and neck cancer, neoadjuvant therapy is recommended before surgery, including neoadjuvant chemotherapy and immunotherapy. there is a significant variation in patients' responses to neoadjuvant therapy, with approximately 37%-52% of patients achieving a complete pathological response after neoadjuvant therapy. current research mainly focuses on the efficacy evaluation of the primary tumor, while there is less research on the treatment efficacy evaluation of cervical lymph nodes. in clinical practice, accurate assessment of the status of cervical lymph nodes after neoadjuvant chemoimmunotherapy in patients with squamous cell carcinoma of the head and neck can directly affect the choice of treatment plan by clinicians, reducing unnecessary neck dissection. in recent years, contrast-enhanced ultrasound has been widely used in the diagnosis of thyroid cancer and other head and neck tumors, as well as in the assessment of the benign and malignant nature of cervical lymph nodes. this study aims to explore the value of contrast-enhanced ultrasound in the assessment of cervical lymph nodes after neoadjuvant chemoimmunotherapy in squamous cell carcinoma of the head and neck, in order to guide clinicians in formulating personalized treatment plans.


Eligibility criteria:
inclusion criteria: * (1) histopathologically confirmed head and neck squamous cell carcinoma; (2) received neoadjuvant chemoimmunotherapy; (3) diagnosed with cn+ by ct/mri before treatment; (4) underwent radical surgical treatment plus cervical lymph node dissection at this center. exclusion criteria: * (1) did not receive a full course of neoadjuvant therapy; (2) history of treatment for head and neck; (3) clinical evidence of distant metastasis found during preoperative examination.
neural mobilization in cervico-brachial neuralgia

Conditions: Cervico Brachialgia

Summary: this study aimed to compare the effectiveness of neural mobilization (nm) combined with conventional rehabilitation versus conventional rehabilitation alone in patients with chronic common cervico-brachial neuralgia (cbn), focusing on pain, cervical range of motion (rom), functional disability, and psychological state. a randomized controlled trial was conducted including patients with chronic cbn. they were randomized into two groups: control group received standard rehabilitation, while nm group received the same treatment with additional nm techniques. evaluations were conducted pre- and post-treatment, assessing pain, cervical rom, functional disability and psychological state via the beck depression inventory.


Eligibility criteria:
inclusion criteria: * patients over 18 years old * with chronic common cbn exclusion criteria: * secondary cbn * prior cervical surgery * cervical trauma * recent central or peripheral neurological conditions * unstable cauda equina lesions, * untreated tumors or infections.

Keywords: cervico-brachial neuralgia neural mobilization pain function
a prospective multicenter clinical trial of mrd-based treatment strategy in children and young adults with aml

Conditions: Acute Myeloid Leukemia, Childhood

Summary: minimal-residual disease (mrd) will be measured either by flow cytometry, or polymerase chain reaction (pcr) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics. patients with initially high-risk group and those with high mrd after 2 initial courses of chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem cells from human leucocyte antigen (hla) matched or haploidentical family donors.

genetic alterations in acute myeloid leukemia (aml) clone are well known prognostic risk factors of aml relapse. standard risk group includes favorable t (15;17) (q22; q21) and inv (16)/t (16;16). high-risk patients have a complex karyotype rearrangement (3 and more), inversion of the long arm in 3rd chromosome and evi1 gene rearrangement, monosomy 5 and 7, translocations involving kmt2a gene and several rare translocations. all other genotype alterations attributed to the moderate risk group. besides genetic factors, detection of the minimal residual disease (mrd) after initial chemotherapy and its decrease rate after 1st postremission chemotherapy with high dose cytarabine and anthracyclines, plays a crucial role in the development of the morphologic relapse. patients with pcr-mrd\ 0,1% - over 70%. in the clinical trial investigators are planning to measure mrd either by immune-phenotype, or pcr methods, in 3 check-points and it will be one of decision-making control parameter for the optimal therapy tactics. patients with initially high-risk group and those with high mrd after 2 initial courses of chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem cells from hla- matched or haploidentical family donors.

Eligibility criteria:
inclusion criteria: 1. de novo acute myeloid leukemia 2. signed informed consent exclusion criteria: diagnosis of: fanconi anemia, acute promyelocytic leukemia, mds, jmml, aml as secondary malignancy, dawn syndrome.

Keywords: aml mrd stem cell transplantation pediatric leukemia haploidentical tcrab-depletion young adult
predictors of response to manual physiotherapy using somatosensory profiles in patients with cervicobrachial pain

Conditions: Cervical Radicular Pain; Cervical Radiculopathy; Cervical Pain

Summary: the goal of this clinical trial is to investigate about the characteristics that predict response to physiotherapy treatment in patients with nerve related neck arm pain. the main question to answer is whether there is a subgroup that responds better to physiotherapy treatment. participants will be assessed for clinical and neurophysiological characteristics prior to treatment. afterwards they will receive 6 sessions of manual physiotherapy treatment along with home nerve gliding exercises once a week. baseline measurements will be taken again after treatment to know if there have been any changes.

during the first visit, socio-demographic data will be collected. then, participants will be assessed using the quantitative sensory testing (qst) to evaluate the excitability of the nervous system. in addition, questionnaires and scales will be used to obtain information on the psychosocial factors involved, neuropathic pain characteristics and on the disability caused by their situation. finally, various clinical tests will be carried out to obtain information on neck movement and irritability at closure of the intervertebral foramen, mechanosensitivity of the upper limb with neurodynamic testing and alterations in sensitivity, strength and myotatic reflexes. also they will be asked for permission to access to their imaging tests. once the pre-treatment data has been obtained, the manual physiotherapy and exercise treatment will begin, which aims to reduce the irritability of the nervous system. once the treatment is completed, the initial measurements will be repeated along with a global rating of change scale to classify patients as responders vs. non-responders.

Eligibility criteria:
inclusion criteria: * subjects with unilateral cervicobrachial pain exclusion criteria: * signs of severe disease, cervical myelopathy, tumour, rheumatic diseases or a neurological pathology of central origin. * cervicobrachial pain of traumatic origin or as a result of whiplash. * previous surgical intervention of the cervical spine.

Keywords: cervicobrachial pain nerve related neck arm pain
safety and efficacy of talactoferrin in addition to standard chemotherapy in patients with non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone


Eligibility criteria:
inclusion criteria: * confirmed locally advanced or metastatic non-small cell lung cancer that is unresectable * at least 1 unirradiated target lesion measurable by recist * adequate hematologic, renal and hepatic function * ecog 0,1 * able to understand and sign an informed consent exclusion criteria: * presence of brain metastases, unless the patient received brain irradiation, including adequate stereotactic radiosurgery, at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 3 weeks prior to randomization * received prior systemic anti-cancer therapy for nsclc * history of allergic reactions to compounds of similar chemical or biologic composition to talactoferrin or the chemotherapy drugs * any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications * history of other malignancies except: (i) adequately treated basal or squamous cell carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other curatively treated solid tumor with no evidence of disease for ≥5 years * uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart failure * serious active infection * psychiatric illness/social situations that would limit study compliance * other uncontrolled serious chronic disease or conditions that in the investigator's opinion could render compliance or follow-up in the protocol problematic * concurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response) * concurrent systemic corticosteroid therapy within 4 weeks prior to randomization, except prophylactic use of steroids prior to paclitaxel administration * known hiv positive or on active anti-retroviral therapy * known hepatitis b surface antigen positive or hepatitis c positive * receipt of any investigational medication within 4 weeks prior to randomization * pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and for 30 days after completion of treatment * sexually active male patients unwilling to practice contraception while participating on the study and up to 30 days after completion of treatment * legal incapacity or limited legal capacity, unless authorization is granted by a legal guardian

Keywords: non small cell lung cancer talactoferrin dendritic cell recruiter and activator dcra immunomodulatory agent lactoferrin
comparison of medial rectus resection and plication in exotropic patients

Conditions: Exotropia

Summary: purpose: to determine the surgical outcomes of the plication technique in comparison with the resection method on exotropic patients. methods: in this randomized clinical trial, a total of 52 exotropic patients (female, 51.9%) who are candidate for medial rectus strengthening will be randomly classified into plication (n=24) and resection (n=28) groups. the comprehensive visual and ocular examinations will be performed on all study subjects and they will be followed- up for three months postoperatively. plication technique is the same as resection up to muscle suturing, in the next step, the sutures are passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures.


Eligibility criteria:
inclusion criteria: patients with a residual exotropia and history of uni- or bilateral lateral rectus recession or recession and resection (r \&r) and those exotropic patients who were going to have already recession and resection (r \& r) operation due to unilateral constant exotropia will be considered as eligible cases to be included. exclusion criteria: subjects with a history of prematurity, intellectual disability, lack of central fixation (nystagmus, eccentric fixation, retinopathy of prematurity) subjects with systemic or other ocular diseases, neurological disorders, uncooperative patients and participants with less than three-month postoperative follow-up will be excluded from this study.